BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2575 related articles for article (PubMed ID: 28143577)

  • 1. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
    Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
    PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minocycline inhibition of microglial rescues nigrostriatal dopaminergic neurodegeneration caused by mutant alpha-synuclein overexpression.
    Wang Y; Wang Q; Yu R; Zhang Q; Zhang Z; Li H; Ren C; Yang R; Niu H
    Aging (Albany NY); 2020 Jul; 12(14):14232-14243. PubMed ID: 32706757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
    J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
    Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease.
    Koprich JB; Johnston TH; Reyes MG; Sun X; Brotchie JM
    Mol Neurodegener; 2010 Oct; 5():43. PubMed ID: 21029459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.
    Gleave JA; Arathoon LR; Trinh D; Lizal KE; Giguère N; Barber JHM; Najarali Z; Khan MH; Thiele SL; Semmen MS; Koprich JB; Brotchie JM; Eubanks JH; Trudeau LE; Nash JE
    Neurobiol Dis; 2017 Oct; 106():133-146. PubMed ID: 28673739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.
    Peneder TM; Scholze P; Berger ML; Reither H; Heinze G; Bertl J; Bauer J; Richfield EK; Hornykiewicz O; Pifl C
    Neuroscience; 2011 Apr; 180():280-92. PubMed ID: 21333719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.
    Musacchio T; Rebenstorff M; Fluri F; Brotchie JM; Volkmann J; Koprich JB; Ip CW
    Ann Neurol; 2017 Jun; 81(6):825-836. PubMed ID: 28470693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
    Khodr CE; Becerra A; Han Y; Bohn MC
    Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
    St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
    J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
    Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
    Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
    Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
    Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 129.